Company Overview: Regeneron Pharmaceuticals, Inc. is a pharmaceutical company incorporated in New York, headquartered in Tarrytown, NY, engaged in the development and commercialization of pharmaceutical preparations (SIC Code 2834) Fiscal Period: Annual report covering the full fiscal year ended December 31, 2025, filed on February 4, 2026 Financial Reporting Structure: Filing includes…

Our analysis rates this filing CAUTIOUS. Regeneron presents an elevated but not critical concern profile. The company faces structural revenue concentration risks and near-term patent/biosimilar headwinds typical of large pharmaceutical companies, but these are manageable challenges rather than…

Concern level: HIGH (6.2/10). Key factors: Three new high-severity risks identified with average severity of 6.7/10, including product pipeline concentration (severity 7) and IP/patent expiration (severity 7); Heavy revenue concentration in two products (EYLEA and LIBTAYO) creates material portfolio vulnerability if either faces competitive, clinical, or regulatory setbacks; EYLEA franchise…

Notable risk changes: EYLEA franchise faces increasing biosimilar competition and market saturation in wet AMD indication, with revenue growth pressure evident in product-level disclosures; Patent expiration timeline for key products creates near-term revenue cliff risk; company must demonstrate successful pipeline advancement to offset losses; Concentration of revenue in two primary products (EYLEA and LIBTAYO)…

The model predicts REGN will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.